Q-omics provides the consensus-scored C5orf49 profile across patient tissues and cancer cell-line models. C5orf49 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C5orf49 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C5orf49 RNA expression shows 15,330 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where C5orf49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf49 survival associations across molecular data types. C5orf49 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf49 RNA expression–survival associations across cancer types. High C5orf49 expression shows unfavorable associations in BLCA, LGG, SKCM and GBM, but favorable associations in KIRP and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C5orf49 RNA expression.
This table summarizes C5orf49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C5orf49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf49 shows lower tumor expression in THCA, LUSC, LUAD and KICH and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher C5orf49 RNA expression in tumor versus normal tissue (log2 FC = +1.065, t-test p < 0.001).
This table shows molecular features associated with C5orf49 in patient tissues and cancer cell lines. In patient samples, C5orf49 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf49 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
